SEC Filing Summary: Vital Therapies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vital Therapies, Inc. on October 22, 2015. The filing reports the entry into a material definitive agreement regarding a public offering of common stock. Note: The request metadata references "IMMUNIC, INC.", but the filing text explicitly identifies the registrant as "Vital Therapies, Inc."
Key Financial Metrics and Transaction Details
- Transaction Type: Public offering of common stock via underwriting agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated.
- Shares Issued: 5,454,546 shares of common stock.
- Overallotment Option: Underwriter granted a 30-day option to purchase up to 818,181 additional shares.
- Expected Net Proceeds: Approximately $27.8 million (excluding overallotment).
- Cash Position: As of September 30, 2015, the company held $59.8 million in cash and cash equivalents.
- Expected Closing Date: October 28, 2015.
Material Changes
The primary material change is the execution of the underwriting agreement to raise capital. The filing does not provide comparative financial data (revenue, profit, margins, or debt) for prior periods, as this is a transactional report rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
The company expects the offering to close on October 28, 2015. The filing includes standard forward-looking statements regarding the timing and size of the offering. Key risks identified include stock market conditions and the company's ability to satisfy conditions to closing in the underwriting agreement. The company disclaims any obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the final closing date of the offering (expected October 28, 2015).
- Confirm whether the underwriter exercised the 30-day overallotment option for an additional 818,181 shares.
- Review the final prospectus supplement for the exact offering price per share and total net proceeds.
- Check subsequent filings for any changes to the company's cash position or use of proceeds.